Product Update

RNS Number:7721K
M.L. Laboratories PLC
07 May 2003



For immediate release                                               7 May 2003

           PERITONEAL DIALYSIS SOLUTION PRODUCT LAUNCHED IN US MARKET
                                      AND
                      MARKETING APPROVAL GRANTED IN JAPAN
                                        
ML Laboratories PLC (ML) announces today that the worldwide licencee of its
icodextrin peritoneal dialysis solution, Baxter Healthcare Corporation (Baxter),
has launched the product in the US market under its trademark 'Extraneal'.

In addition ML also announces that Baxter has received marketing approval from
the regulatory authorities in Japan which will enable the product to be launched
in Japan which ML anticipates will be received later this year.

Baxter considers Extraneal represents a significant achievement in its continued
effort to develop innovative therapies for people with kidney disease.

Of the estimated one million people worldwide suffering from chronic kidney
disease (ESRD) who are treated with some form of dialysis therapy, 10 to 15
percent use peritoneal dialysis. In the US, more than 300,000 people, or just
over one in 1,000 people, are being treated for ESRD which is growing
approximately six percent annually. In Japan, approximately 220,000 ESRD
patients are being treated with some form of dialysis.

Extraneal is currently approved for marketing in 36 countries and more than
10,000 patients worldwide are using the solution every day.

Stuart Sim, Chairman of ML said today 'The US launch of Extraneal and the grant
of marketing approval in Japan represents excellent news as they offer the
prospect of significant royalty income from these large markets'.


For further information please contact:

Mr. Stuart Sim      Chairman, ML Laboratories PLC     [phone]

Graham Herring      Weber Shandwick Square Mile       [phone]


Notes to Editors:


ML LABORATORIES PLC

ML is a biopharmaceutical product development company with a pipeline of future
products targeted at specialist markets. ML's activities are supported by a
growing income stream from marketed products it has successfully developed and
licensed to other pharmaceutical companies which include Baxter, Shire and
Celltech.

New therapeutic products in clinical development include cancer treatments for
liver, head, neck and prostate cancer, a pain management compound prepared to
enter Phase III studies, a preventative of sexually transmitted infections,
including HIV and a phosphate binder to assist the management of kidney failure.
ML's portfolio of early stage development projects includes unique polymer/drug
molecules to provide safer and more potent cancer chemotherapy and technologies
for use in the discovery and manufacture of biotechnology products.

In addition ML provides inhaled drug delivery solutions to the global
pharmaceutical industry through its dedicated respiratory subsidiary Innovata
Biomed.

For further information on Extraneal see www.baxter.com/extraneal







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
PRLUNARROORVRUR